NeuroPace
Clinical trials sponsored by NeuroPace, explained in plain language.
NeuroPace makes an implantable brain-responsive neurostimulation device for epilepsy.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Brain implant shows promise for Hard-to-Treat seizures in rare epilepsy Results expected Nov 2026 (estimated)
- Brain implant that fires at seizures tested in teens Results expected Feb 2027 (estimated)
-
Brain implant shows promise for Hard-to-Treat seizures in rare epilepsy
Disease control OngoingThis study tests a brain-responsive neurostimulation system in 24 people aged 12 and older with Lennox-Gastaut syndrome whose seizures are not controlled by medication. The device detects and responds to seizure activity in the brain to reduce drop seizures. The goal is to see if…
Phase 2 • Sponsor: NeuroPace • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Brain implant that fires at seizures tested in teens
Symptom relief By invitation onlyThe NeuroPace RNS System is an implanted brain stimulator approved for adults with focal epilepsy that medicines cannot control. Researchers are gathering real-world data on how safe and effective the device is in adolescents aged 12 to 17 who already received it in routine care.…
Sponsor: NeuroPace • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC